The authors demonstrated that EGCG ameliorated the HFD-induced obesity in part by attenuating hypothalamic inflammation through the inhibition of NF-kB and Signal transducer and activator of transcription 3 (STAT3) phosphorylation, as well as the expression and release of inflammatory cytokines, such as TNF-a, IL-6, and IL-1b [185]. Here, NFKB1 is linked to obesity disorder.